Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

The Grammy-nominated musicians discuss what's helping them manage, and why they’re using their platform to reach the Black ...

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

“My vision is that every American is wearing a wearable within four years,” he said at a congressional hearing last week. It ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...